Endurant Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Endurant Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-12,031	Closed	-$462K	–	79
2019 Q1	$462K	Buy	+12,031	New	+$525K	0.18%	61

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Endurant Capital Management's VTGN Position: Q2 2019 in Review

Endurant Capital Management sold out of VistaGen Therapeutics (VTGN) in Q2 2019, closing a stake of 12,031 shares — an estimated $462K sold.

Endurant Capital Management first reported a position in VTGN in Q1 2019 and held it in 1 quarter. The position peaked at $462K in Q1 2019. 21 funds tracked by Wall St. Rank hold VTGN as of Q2 2019.

Endurant Capital Management reported no remaining VistaGen Therapeutics position as of Q2 2019 after selling out during the quarter.
Endurant Capital Management sold 12,031 VistaGen Therapeutics shares in Q2 2019, an estimated $462K.
Endurant Capital Management first reported a position in VistaGen Therapeutics in Q1 2019 and held it in 1 quarter.
Endurant Capital Management's VistaGen Therapeutics position peaked at $462K in Q1 2019.
21 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2019.

Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.